Human Genome Sciences Stock Hits New 52-Week Low (HGSI)

NEW YORK ( TheStreet) -- Human Genome Sciences Inc (Nasdaq: HGSI) hit a new 52-week low Monday as it is currently trading at $11.04, below its previous 52-week low of $11.05 with 3.1 million shares traded as of 12:56 p.m. ET. Average volume has been 4.6 million shares over the past 30 days.

Human Genome Sciences has a market cap of $2.4 billion and is part of the health care sector and drugs industry. Shares are down 46.6% year to date as of the close of trading on Friday.

Human Genome Sciences, Inc. operates as a biopharmaceutical company. Its principal products in development include BENLYSTA for systemic lupus erythematosus; and raxibacumab for inhalation anthrax.
  • Practice your HGSI trading strategies and win cash in our stock game.

TheStreet Ratings rates Human Genome Sciences as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, generally weak debt management, disappointing return on equity and weak operating cash flow. You can view the full Human Genome Sciences Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.

null

More from Markets

General Electric Booted From Dow, Replaced by Walgreens

General Electric Booted From Dow, Replaced by Walgreens

European Union Says Tariffs on U.S. Imports Will Kick In on June 22

European Union Says Tariffs on U.S. Imports Will Kick In on June 22

Stocks Rise, GE Dropped From the Dow, Starbucks, Oracle - 5 Things You Must Know

Stocks Rise, GE Dropped From the Dow, Starbucks, Oracle - 5 Things You Must Know

Global Stocks Rebound But US-China Trade War Concerns Keep Investors on Edge

Global Stocks Rebound But US-China Trade War Concerns Keep Investors on Edge

GE Loses Its Spot on the Dow and 4 Other Stories to Watch Wednesday Morning

GE Loses Its Spot on the Dow and 4 Other Stories to Watch Wednesday Morning